{
  "abstract": "Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive B-cell lymphoma characterized by pronounced heterogeneity. Patients with relapsed/refractory (R/R) disease after standard R-CHOP regimen face an extremely poor prognosis with subsequent salvage lines. Although chimeric antigen receptor T-cell (CAR-T) therapy represents a breakthrough option for R/R DLBCL, its clinical utility is frequently constrained by various real-world factors in elderly patients. As an alternative T-cell-engaging modality, CD3×CD20 bispecific antibodies (BsAbs) have demonstrated robust efficacy in R/R DLBCL. Herein, we report a 70-year-old male with primary refractory DLBCL harboring co-existing TP53 and CD58 mutations. The patient was refractory to prior lines of therapy, including R-CDOP(rituximab, cyclophosphamide, liposomal doxorubicin, vincristine, and prednisone), R-GemOx(rituximab, gemcitabine, and oxaliplatin), a BTK inhibitor (zanubrutinib, 160 mg bid), and Pola-BR regimen (polatuzumab vedotin, bendamustine, and rituximab). Remarkably, he achieved a sustained CR following 12 cycles of glofitamab monotherapy and subsequent the XPO1 inhibitor selinexor maintenance, complicated solely by a manageable tumor flare reaction (TFR). This case suggests that glofitamab, potentially followed by targeted maintenance, offers a promising, highly effective, and manageable treatment strategy for elderly patients with ultra-high-risk, multi-line refractory DLBCL.",
  "abstract_shown": true,
  "affiliations": [
    "Lanzhou University Second Hospital",
    "Lanzhou University"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 8,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Yurong Zhang"
    },
    {
      "affs": [
        0
      ],
      "name": "Huan Liu"
    },
    {
      "affs": [
        0
      ],
      "name": "Liangliang Li"
    },
    {
      "affs": [
        0
      ],
      "name": "Chune Wang"
    },
    {
      "affs": [
        1
      ],
      "name": "Jiajia Cao"
    },
    {
      "affs": [
        0
      ],
      "name": "Pengyun Zeng"
    },
    {
      "affs": [
        0
      ],
      "name": "Lingling Yue"
    },
    {
      "affs": [
        0
      ],
      "name": "Chongyang Wu"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/6sxetesvmjpe0.bib",
  "cited_by": 0,
  "doi": "10.3389/fonc.2026.1908174",
  "fulltext_url": null,
  "id": "6sxetesvmjpe0",
  "issns": [
    "2234-943X"
  ],
  "landing_url": "https://www.frontiersin.org/articles/10.3389/fonc.2026.1908174/full",
  "language": null,
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2734|Lymphoma Diagnosis and Treatment"
    ]
  ],
  "openalex": "W7224116146",
  "pdf_url": "https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1908174/pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-10-28",
  "publisher": "Frontiers Media SA",
  "ris": "https://research.draconitic.com/paper/6sxetesvmjpe0.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:20:14Z",
      "native_id": "10.3389/fonc.2026.1908174",
      "source": "crossref",
      "url": "https://www.frontiersin.org/articles/10.3389/fonc.2026.1908174/full"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "issn:2234-943X",
      "subfield": "oncology"
    }
  ],
  "title": "Successful salvage therapy with glofitamab followed by selinexor maintenance in an elderly patient with primary refractory diffuse large b-cell lymphoma harboring TP53 and CD58 mutations: a case report and literature review",
  "title_text": "Successful salvage therapy with glofitamab followed by selinexor maintenance in an elderly patient with primary refractory diffuse large b-cell lymphoma harboring TP53 and CD58 mutations: a case report and literature review",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:20:14Z",
  "url": "https://research.draconitic.com/paper/6sxetesvmjpe0",
  "venue": "Frontiers in Oncology",
  "versions": []
}